Robust Clinical Data Supports TECNIS PureSee IOL Performance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy JNJ?
Source: Newsfilter
- Clinical Study Results: The TECNIS PureSee IOL demonstrated exceptional distance and intermediate vision across two major studies in the U.S., Europe, and Asia-Pacific, with 91% of patients reporting minimal bothersome glare, 93% no halos, and 92% no starbursts, indicating significant advantages in visual quality.
- High Patient Satisfaction: A real-world observational study involving 293 patients revealed that 96% reported spectacle independence for distance, 95% for intermediate, and 61% for near vision, showcasing the success of TECNIS PureSee IOL in reducing reliance on glasses.
- Enhanced Visual Outcomes: In a U.S. prospective randomized clinical trial with 200 patients, TECNIS PureSee IOL provided high-quality distance vision and significantly improved intermediate vision compared to monofocal IOLs, with low levels of visual disturbances, further boosting surgical confidence.
- Commitment to Innovation: The data presented at the 2026 ASCRS Annual Meeting underscores Johnson & Johnson's commitment to innovation in vision health, aiming to advance technology through rigorous clinical research to enhance patient visual experiences.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JNJ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 241.310
Low
190.00
Averages
218.50
High
240.00
Current: 241.310
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Strong Growth Amidst Significant Challenges for Johnson & Johnson
- Consistent Revenue Growth: Despite facing challenges such as patent expirations and drug pricing negotiations, Johnson & Johnson is projected to exceed $100 billion in revenue for 2023, demonstrating resilience and a strong market position in a tough environment.
- Significant Patent Risks: Johnson & Johnson lost patent protection for Stelara in 2023, which peaked at $10.9 billion in sales, accounting for nearly 13% of total revenue, posing a potential threat to future earnings.
- Robust Financial Foundation: The company holds an AAA rating from S&P Global, indicating a strong financial position capable of weathering potential lawsuits and market fluctuations, thereby enhancing investor confidence.
- Stable Dividend Policy: With 63 consecutive years of dividend increases, Johnson & Johnson is an ideal choice for investors seeking stable income amid economic uncertainty, further solidifying its leadership in the healthcare sector.
See More
Earnings Season Kicks Off Amid Investor Anticipation
- Earnings Wave: This week, 27 S&P 500 companies, including banking giants like JPMorgan Chase and Goldman Sachs, are set to report earnings, and despite the tense situation in the Middle East, analysts expect a strong earnings season with S&P 500 first-quarter profits projected to grow 13% year-over-year, marking the sixth consecutive quarter of double-digit profit growth.
- Goldman Sachs Forecast: Goldman Sachs is expected to report earnings on Monday, with analysts forecasting double-digit earnings and revenue growth driven by strong performance in equities trading, asset, and wealth management units, and historical data shows the bank beats profit expectations 87% of the time.
- Johnson & Johnson Momentum: Johnson & Johnson is set to report earnings on Tuesday, and while its earnings per share are expected to decline slightly year-over-year, the stock has risen 15% year-to-date, prompting analysts to watch for potential stock price boosts post-report, with a historical 95% success rate in beating earnings expectations.
- Morgan Stanley Growth Outlook: Morgan Stanley is scheduled to report earnings on Thursday, with analysts predicting a roughly 15% year-on-year growth in earnings, primarily benefiting from its wealth management division, and historical data indicates the firm has beaten earnings expectations in every quarter since early 2023.
See More
Nvidia's AI Chip Revenue Soars 73% Amid Market Dominance
- Significant Revenue Growth: Nvidia reported a staggering $68 billion in revenue for the latest quarter, marking a 73% year-over-year increase, with forecasts predicting a 77% rise in the upcoming quarter, highlighting robust demand and growth potential in the AI chip market.
- Strengthened Competitive Advantage: Despite competition from AMD and Amazon, Nvidia continues to attract customers with the superior performance of its latest GPUs, ensuring its leadership position in the rapidly growing AI market.
- CUDA Technology Edge: Nvidia's CUDA parallel computing platform has been installed on over 100 million computers, serving as a core competitive advantage that allows its GPUs to expand from gaming into broader computational applications, particularly in AI.
- Investment Opportunity Emerges: Nvidia's stock is currently trading at a low valuation of 21 times forward earnings, presenting an attractive entry point for investors, and combined with its strong market moat, suggests sustainable growth potential in the future.
See More
Nvidia's Revenue Soars 73%, Highlighting AI Leadership
- Significant Revenue Growth: Nvidia reported a staggering $68 billion in revenue for the latest quarter, marking a 73% year-over-year increase, with analysts forecasting a 77% growth for the current quarter, underscoring the company's strong leadership in the AI chip market.
- Frequent Technology Updates: Nvidia consistently updates its technology to maintain a competitive edge, particularly in GPU performance, and despite facing rivals like AMD and Amazon, its latest GPUs continue to outperform, attracting a substantial customer base.
- CUDA Platform Advantage: The CUDA parallel computing platform developed by Nvidia is installed on over 100 million computers, serving as a core competitive advantage that ensures developers can continuously access leading technology and drive widespread adoption of AI applications.
- Investment Opportunity Emerges: With Nvidia's stock trading at a forward P/E ratio of 21, currently at a relatively low level, it presents a compelling entry point for investors, and combined with its strong market moat, future growth is expected to continue.
See More
Historical Trends Indicate Imminent Stock Market Recovery
- Opportunity for Recovery: Historical data indicates that major indexes typically experience significant gains in the 12 to 36 months following corrections, particularly during the third year of a presidential term, suggesting investors should seize this moment.
- Market Performance Patterns: Analysis by Charles Schwab from 1933 to 2015 reveals that the average returns of the S&P 500 show weaker performance in the first two years of a presidential term, with rebounds often occurring in the third year, highlighting the importance of recognizing this cyclical trend.
- Timing the Market: While buying stocks during downturns can be intimidating for many investors, history shows that such periods of anxiety often precede strong recoveries, encouraging investors to remain patient and ready to act.
- Long-Term Investment Strategy: For long-term investors, the best time to buy is always “now,” as the value of time in the market outweighs the importance of timing, with historical evidence suggesting that holding investments long enough will yield positive returns.
See More
Imminent Best Time to Buy Stocks
- Historical Return Analysis: According to Charles Schwab's analysis from 1933 to 2015, the average return for the S&P 500 in the third year of a presidential term was 13.5%, indicating that significant gains are typically available during this period, thus providing an optimistic market outlook ahead of the 2026 mid-term elections.
- Market Correction Opportunities: Recently, both the Dow Jones Industrial Average and the Nasdaq Composite Index entered correction territory, and historical data shows that major index corrections are often followed by significant rebounds, as evidenced by the Nasdaq's nearly 44% return post-pandemic in 2020, highlighting investment opportunities amid uncertainty.
- Political Cycle Impact: The Presidential Election Cycle Theory suggests that the stock market tends to perform poorly in the first two years of a presidential term but usually rebounds in the third year, prompting investors to consider the potential policy changes and market stability that upcoming mid-term elections may bring, thus seizing investment opportunities.
- Long-Term Investment Strategy: Despite current market volatility, history indicates that investors who hold the Dow, Nasdaq, or S&P 500 for the long term will ultimately profit, making it particularly advantageous for those with cash on the sidelines to invest now.
See More
Strong Growth Amidst Significant Challenges for Johnson & Johnson
- Consistent Revenue Growth: Despite facing challenges such as patent expirations and drug pricing negotiations, Johnson & Johnson is projected to exceed $100 billion in revenue for 2023, demonstrating resilience and a strong market position in a tough environment.
- Significant Patent Risks: Johnson & Johnson lost patent protection for Stelara in 2023, which peaked at $10.9 billion in sales, accounting for nearly 13% of total revenue, posing a potential threat to future earnings.
- Robust Financial Foundation: The company holds an AAA rating from S&P Global, indicating a strong financial position capable of weathering potential lawsuits and market fluctuations, thereby enhancing investor confidence.
- Stable Dividend Policy: With 63 consecutive years of dividend increases, Johnson & Johnson is an ideal choice for investors seeking stable income amid economic uncertainty, further solidifying its leadership in the healthcare sector.
See More
Earnings Season Kicks Off Amid Investor Anticipation
- Earnings Wave: This week, 27 S&P 500 companies, including banking giants like JPMorgan Chase and Goldman Sachs, are set to report earnings, and despite the tense situation in the Middle East, analysts expect a strong earnings season with S&P 500 first-quarter profits projected to grow 13% year-over-year, marking the sixth consecutive quarter of double-digit profit growth.
- Goldman Sachs Forecast: Goldman Sachs is expected to report earnings on Monday, with analysts forecasting double-digit earnings and revenue growth driven by strong performance in equities trading, asset, and wealth management units, and historical data shows the bank beats profit expectations 87% of the time.
- Johnson & Johnson Momentum: Johnson & Johnson is set to report earnings on Tuesday, and while its earnings per share are expected to decline slightly year-over-year, the stock has risen 15% year-to-date, prompting analysts to watch for potential stock price boosts post-report, with a historical 95% success rate in beating earnings expectations.
- Morgan Stanley Growth Outlook: Morgan Stanley is scheduled to report earnings on Thursday, with analysts predicting a roughly 15% year-on-year growth in earnings, primarily benefiting from its wealth management division, and historical data indicates the firm has beaten earnings expectations in every quarter since early 2023.
See More
Nvidia's AI Chip Revenue Soars 73% Amid Market Dominance
- Significant Revenue Growth: Nvidia reported a staggering $68 billion in revenue for the latest quarter, marking a 73% year-over-year increase, with forecasts predicting a 77% rise in the upcoming quarter, highlighting robust demand and growth potential in the AI chip market.
- Strengthened Competitive Advantage: Despite competition from AMD and Amazon, Nvidia continues to attract customers with the superior performance of its latest GPUs, ensuring its leadership position in the rapidly growing AI market.
- CUDA Technology Edge: Nvidia's CUDA parallel computing platform has been installed on over 100 million computers, serving as a core competitive advantage that allows its GPUs to expand from gaming into broader computational applications, particularly in AI.
- Investment Opportunity Emerges: Nvidia's stock is currently trading at a low valuation of 21 times forward earnings, presenting an attractive entry point for investors, and combined with its strong market moat, suggests sustainable growth potential in the future.
See More
Nvidia's Revenue Soars 73%, Highlighting AI Leadership
- Significant Revenue Growth: Nvidia reported a staggering $68 billion in revenue for the latest quarter, marking a 73% year-over-year increase, with analysts forecasting a 77% growth for the current quarter, underscoring the company's strong leadership in the AI chip market.
- Frequent Technology Updates: Nvidia consistently updates its technology to maintain a competitive edge, particularly in GPU performance, and despite facing rivals like AMD and Amazon, its latest GPUs continue to outperform, attracting a substantial customer base.
- CUDA Platform Advantage: The CUDA parallel computing platform developed by Nvidia is installed on over 100 million computers, serving as a core competitive advantage that ensures developers can continuously access leading technology and drive widespread adoption of AI applications.
- Investment Opportunity Emerges: With Nvidia's stock trading at a forward P/E ratio of 21, currently at a relatively low level, it presents a compelling entry point for investors, and combined with its strong market moat, future growth is expected to continue.
See More
Historical Trends Indicate Imminent Stock Market Recovery
- Opportunity for Recovery: Historical data indicates that major indexes typically experience significant gains in the 12 to 36 months following corrections, particularly during the third year of a presidential term, suggesting investors should seize this moment.
- Market Performance Patterns: Analysis by Charles Schwab from 1933 to 2015 reveals that the average returns of the S&P 500 show weaker performance in the first two years of a presidential term, with rebounds often occurring in the third year, highlighting the importance of recognizing this cyclical trend.
- Timing the Market: While buying stocks during downturns can be intimidating for many investors, history shows that such periods of anxiety often precede strong recoveries, encouraging investors to remain patient and ready to act.
- Long-Term Investment Strategy: For long-term investors, the best time to buy is always “now,” as the value of time in the market outweighs the importance of timing, with historical evidence suggesting that holding investments long enough will yield positive returns.
See More
Imminent Best Time to Buy Stocks
- Historical Return Analysis: According to Charles Schwab's analysis from 1933 to 2015, the average return for the S&P 500 in the third year of a presidential term was 13.5%, indicating that significant gains are typically available during this period, thus providing an optimistic market outlook ahead of the 2026 mid-term elections.
- Market Correction Opportunities: Recently, both the Dow Jones Industrial Average and the Nasdaq Composite Index entered correction territory, and historical data shows that major index corrections are often followed by significant rebounds, as evidenced by the Nasdaq's nearly 44% return post-pandemic in 2020, highlighting investment opportunities amid uncertainty.
- Political Cycle Impact: The Presidential Election Cycle Theory suggests that the stock market tends to perform poorly in the first two years of a presidential term but usually rebounds in the third year, prompting investors to consider the potential policy changes and market stability that upcoming mid-term elections may bring, thus seizing investment opportunities.
- Long-Term Investment Strategy: Despite current market volatility, history indicates that investors who hold the Dow, Nasdaq, or S&P 500 for the long term will ultimately profit, making it particularly advantageous for those with cash on the sidelines to invest now.
See More
